The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

A study presented at the 2025 Annual Meeting of the American Academy of Orthopaedic Surgeons examined the relationship between the patient's last dose of Ozempic, a common GLP-1, and ...

The market for GLP-1 agonist medications—used to treat diabetes and obesity—has skyrocketed in the last few years, and Lemme is “hoping to cash in on the GLP-1 agonist craze and swindle Americans into ...

MONDAY, March 10, 2025 (HealthDay News) -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic ...